Advances in cell-laden hydrogels for delivering therapeutics

Click to increase image sizeClick to decrease image size

Acknowledgments

The authors wish to thank project SAF2016-76150-R from the Spanish Ministry of Economy, Industry and Competitiveness and intellectual and technical assistance from the ICTS ‘NANBIOSIS’, more specifically by the Drug Formulation Unit (U10) of the CIBER in Bioengineering, Biomaterials & Nanomedicine (CIBER-BBN) at the University of the Basque Country (UPV/EHU).

Declaration of interest

G Orive is scientific advisor of CapCell Biologics. D Emerich is employed at Gloriana Therapeutics,inc. developing encapsulated cell products for CNS diseases. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer Disclosures

Peer reviewers on this manuscript have no relevant financial relationships or otherwise to disclose.

Additional information

Funding

We also appreciate the support from the Basque Country Government (Grupos Consolidados, No ref: IT907-16, ELKARTEK 16/77) and La Marató de TV3 Foundation (Project 332/C/2016 Encapsulated Synthetic Cellular Circuits to Restore Glycemic Control in Type 1 Diabetes). MC Echave also thanks the Basque Country Government (Departamento de Educación, Universidades e Investigación) for a granted fellowship. A Dolatshahi-Pirouz would like to acknowledge the Danish Council for Independent Research (Technology and Production Sciences, 5054–00142B) and the Villum Foundation (10103). This work is also part of the VIDI research programme with project number R0004387, which is (partly) financed by the Netherlands Organization for Scientific Research (NWO).